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Allograft carotid artery as a
systemic-to-pulmonary conduit
Betsy Jane Evans, MD, and Stephen Westaby, MD, Oxford, UK
Synthetic polytetrafluoroethylene grafts are establishedconduits for palliative systemic-to-pulmonary arteryshunting in infants with cyanotic congenital heart dis-ease.1 Although readily available, these conduits are
stiff, may kink, and are prone to thrombosis. There are technical
difficulties in anastomosing synthetic material to small, thin-
walled infant pulmonary arteries, sometimes resulting in bleeding
or stenosis. As an alternative, we present our experience with
allograft carotid artery conduits as systemic–pulmonary shunts.
Clinical Summary
Between 2000 and 2006, 30 carotid allografts were employed in 27
infants with cyanotic congenital heart disease. Twenty-five mod-
ified Blalock shunts and 4 central shunts were implanted. One
infant received a carotid allograft to create an absent right pulmo-
nary artery (see below).
All carotid allografts were supplied from the Oxford Valve
Bank. They were collected from valve donors at autopsy and
antibiotic treated, cryopreserved, stored, and thawed according to
the Guidelines of the UK National Tissue Bank. The vessels
ranged from 4 to 7 mm in diameter. Standard operative techniques
(including intraoperative heparinization) were used to create the
shunts, and all patients received postoperative antiplatelet ther-
apy with aspirin. Pa-
tients were followed
with echocardiography
and angiography be-
fore corrective surgery
up to 48 months (mean
follow-up: 12.4  3.4
months; Figure 1, A).
This biologic graft
was very easy to su-
ture, with no intraoper-
ative bleeding in any
case. The heparin was
not reversed at the con-
clusion of the procedure. No patient had acute or chronic graft
thrombosis, perigraft leak, or infection. One infant with total anom-
alous pulmonary venous drainage (TAPVD) and pulmonary atresia
died suddenly 12 hours after complete correction with a central shunt.
At autopsy the 5  5–mm shunt was patent and the TAPVD repair
satisfactory. One shunt showed narrowing at 24 months in an infant
with pulmonary atresia (Figure 1, B). Histologic assessment of the
allograft revealed chronic inflammatory changes compatible with
tissue rejection. A contralateral shunt was inserted.
In one 4.2-kg infant with an absent right pulmonary artery and
severe pulmonary hypertension in the left lung, a 4-mm modified
Blalock shunt was first implanted in the hilar arterial remnant. Six
weeks later, a second 7-mm carotid allograft was used to create a
neo-right pulmonary artery. This greatly reduced the pulmonary
artery pressure. We do not believe that this reconstruction would
be possible with synthetic shunt material.
When the major corrective procedures were performed, the shunt
was easy to locate and divide. A histologic section of a 2-year-old
shunt is shown in Figure 2. Elastic van Gieson solution was used to
stain the elastic fibers in the allograft. Focal intimal hyperplasia is
present, but there is no inflammatory response or calcification.
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Figure 1. A, Allograft shunt at 2 years.
B, Shunt in which suspected tissue
rejection caused decreased flow at 6
months. A second contralateral shunt
was implanted. This was the only case
in which an inflammatory response or
rejection was suspected.
Brief Communications
The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1367
Discussion
Carotid artery allografts offer distinct advantages over synthetic
grafts, particularly in small infants. Human tissue demonstrates no
oozing of blood or serous leakage from the suture holes and is
more resistant to infection than are synthetic materials. The lack of
thrombogenicity is also a major advantage when using biologic
tissue. In this series, all shunts remained patent, even in the graft that
narrowed through a suspected immunologic response. In the ab-
sence of a local tissue bank, the availability of human carotid
arteries is problematic. So far, the potential uses of donated blood
vessels are underestimated. For example, we use descending aortic
tubes to improve the safety of left ventricular assist device cannu-
lation and ascending aorta or pulmonary artery wall as patch
material where eventual stiffening and calcification is unimportant.
Accordingly, we obtain as much healthy vascular tissue as possible
when harvesting aortic and pulmonary valves from cadaveric
donors. The risk of immunoreactivity has not proven to be of
importance in the short term between shunting and the corrective
procedure. Bogats and colleagues2 and Tam and associates3 have
reported the use of saphenous vein allografts as an alternative for
modified Blalock shunts. In their series there was no fibrosis or
calcification seen in 4 patients up to 55 months.2
In conclusion, the use of carotid allograft facilitates the micro-
vascular anastomoses in infants with cyanotic congenital heart
disease. These conduits have a very low propensity for thrombosis,
and the potential for immunogenecity does not preclude their use.
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Unusual systemic venous return with absence of superior caval veins
Phalla Ou, MD,a Giulio Calcagni, MD,b Davide Marini, MD,b Jerome Le Bidois, MD,b Pietro Gallo, MD,c
Francis Brunelle, MD, PhD,a and Damien Bonnet, MD, PhD,b Paris, France, and Rome, Italy
T he absence of the right superior vena cava in situssolitus is a rare anomaly. It is usually associated withpersistence of the left superior vena cava or other car-diac abnormalities.1 We report here an extremely un-
common case of bilateral absence of the superior vena cava, with no
associated cardiac anomaly, evaluated through a high-resolution com-
puted tomography (CT) scan.
Clinical Summary
A 14-month-old boy was admitted to our department because of a
cardiac murmur discovered during a routine pediatric evaluation.
On physical examination, a systolic heart murmur of grade 1/6 to 2/6
was found. No chronic heart failure or syndromic dysmorphism had
been found. The electrocardiogram showed sinus rhythm and no
evidence of atrioventricular arrhythmia. A transthoracic echocardio-
gram found a situs solitus, levocardia with atrioventricular and ven-
triculoarterial concordance, normal-sized ventricles, normal intracar-
diac anatomy, and the inferior vena cava draining normally into the
right atrium. No superior caval vein could be seen.
We performed cardiac CT scanning to confirm the presumptive
diagnosis: 64-slice CT scan (LightSpeed VCT; General Electric,
Milwaukee, Wis), slice thickness 0.625 mm, speed of rotation 0.4
second, pitch 0.9, 80 kV, milliamperes modulated during the
acquisition, and peripheral injection of contrast agent (iohexol 300
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Figure 2. Histologic section taken from an allograft shunt 18
months after implantation, showing no signs of inflammation or
rejection.
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